Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Protocol for Risk-adapted Stereotactic Body Radio Therapy for Stage T1-T3N0 Non-Small Cell Lung Carcinoma

NCT02224547 is registered in ClinicalTrials.gov with Universitair Ziekenhuis Brussel as lead sponsor.

NCT NCT02224547
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02224547 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Protocol for Risk-adapted Stereotactic Body Radio Therapy for Stage T1-T3N0 Non-Small Cell Lung Carcinoma
Lead sponsor
Universitair Ziekenhuis Brussel
Phase
Phase 2
Overall status
Unknown status
Start date
January 31, 2013
Completion date
Not reported
Enrollment
58 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung carcinoma